| Ryan Wade, MD | |
|
2015 2nd Ave Ste 101, Summerville, SC 29486-7889 | |
| (843) 737-9465 | |
| Not Available |
| Full Name | Ryan Wade |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 2015 2nd Ave Ste 101, Summerville, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528473469 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 2017-01215 (North Carolina) | Secondary |
| 208000000X | Pediatrics | 86509 (South Carolina) | Primary |
| Entity Name | Dlp Western Carolina Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609281641 PECOS PAC ID: 9032338975 Enrollment ID: O20140908002531 |
News Archive
According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
A new study has shown that taking certain commonly used painkillers for long periods or in high doses increases the risk of heart attacks or strokes. The study comes from researchers from Bern University and is published in the British Medical Journal.
Crimson Life Sciences, a division of TransPerfect and the world's only ISO 13485 and ISO 14971-certified translation provider, today announced the publication of their Japan Medical Device Digest, a free monthly report that provides English translations of Japanese-language news items.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Wade, MD 2067 Charlie Hall Blvd, Charleston, SC 29414-5834 Ph: (843) 573-2535 | Ryan Wade, MD 2015 2nd Ave Ste 101, Summerville, SC 29486-7889 Ph: (843) 737-9465 |
News Archive
According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
A new study has shown that taking certain commonly used painkillers for long periods or in high doses increases the risk of heart attacks or strokes. The study comes from researchers from Bern University and is published in the British Medical Journal.
Crimson Life Sciences, a division of TransPerfect and the world's only ISO 13485 and ISO 14971-certified translation provider, today announced the publication of their Japan Medical Device Digest, a free monthly report that provides English translations of Japanese-language news items.
› Verified 8 days ago
Dr. Esther Spiegle Wilson, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 202 Bentons Lodge Rd, Summerville, SC 29485 Phone: 843-871-2588 | |
Dr. Emily Kathleen Johnson, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2016 1st Ave, Summerville, SC 29486 Phone: 843-873-4545 Fax: 843-873-1561 | |
Mr. Benjamin L Rodgers, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 748 Orangeburg Rd, Summerville, SC 29483 Phone: 843-832-8606 Fax: 843-285-7272 | |
Mr. Mark Jeffrey Mccall, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 312 Midland Pkwy, Summerville, SC 29485 Phone: 843-875-6262 Fax: 843-873-7958 | |
Mr. John William Pence Sr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1815 Old Trolley Rd, Summerville, SC 29485 Phone: 843-875-0440 Fax: 843-875-0442 | |
Seth Winkler, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 312 Midland Pkwy, Summerville, SC 29485 Phone: 843-875-6262 | |
Dr. Shanika Damien Rutledge, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2015 2nd Ave Ste 101, Summerville, SC 29486 Phone: 843-573-2535 Fax: 843-573-2534 |